



October 5, 2015

Company name	3 - D	M a t r i x ,	L t d .
A d d r e s s	3-2-4 Kojimachi, Chiyoda-ku, Tokyo		
P r e s i d e n t	Kentaro Takamura		
C o d e N u m b e r	7777		
C o n t a c t	Director	Tomoyuki Arai	
T E L	+81 3 (3511)3440		

Partnership Agreement concluded with Maquet Australia Pty Ltd regarding sales and marketing of absorbable local hemostat 「PuraStat®」 in Australia

Our consolidated subsidiary in Singapore, 3-D Matrix Asia Pte. Ltd. (“3DMA”), and Maquet Australia Pty Ltd (“Maquet”, head office located at Level 2, 4 Talavera Road, Macquarie Park, NSW 2133, Australia) have entered into a partnership agreement for sales and marketing of our absorbable local hemostat “PuraStat®” in Australia on September 29th, 2015.

In this agreement, 3DMA will grant a non-exclusive sales and marketing license to Maquet in Australia. Once product registration by Maquet is completed, Maquet will then market the product within Australia through their sales network. Maquet expects that “PuraStat®” will be registered and commercial sale will take place by end of this fiscal year.

Based on this agreement, we now have access to sales network in Oceania. Australia is a key market with a population of over 23 million people, average medical expenditure per capita of JPY 730,000*¹ (Japan: JPY 470,000*¹), and 300,000 cardiovascular surgery cases per year*² (Japan: 63,800 cases*³). As Australia's medical and surgical equipment industry is expected to see 7% growth, 3-D Matrix group will continue to develop and strengthen sales platform in the Asia Pacific region through 3DMA.

This announcement does not influence the earning forecast of the company at this moment. However, we will make necessary announcements when it is deemed that there is any influence.

Reference:

*1: The World Bank, World Development Indicators (2013), Retrieved from

<http://databank.worldbank.org/data/reports.aspx?source=world-development-indicators&Type=TABLE>

*2: National Heart Foundation of Australia, “Australian Heart Disease Statistics 2014” (Procedures considered : Atrium, Ventricle, Valve Procedure, Pericardium, Coronary Arteries, Aorta only)

*3: Masuda M. “Thoracic and Cardiovascular Surgery in Japan During 2012.” *Gen Thorac Cardiovasc Surg* (2014) 62:734-764.